Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody
Authors
Keywords
T cells, Macaque, Antibodies, Cytotoxic T cells, Cloning, Flow cytometry, Cytokines, Regulatory T cells
Journal
PLoS One
Volume 13, Issue 4, Pages e0191926
Publisher
Public Library of Science (PLoS)
Online
2018-04-05
DOI
10.1371/journal.pone.0191926
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)
- (2017) M. Sznol et al. JOURNAL OF CLINICAL ONCOLOGY
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- (2016) Scott Antonia et al. LANCET ONCOLOGY
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Superantigens hyperinduce inflammatory cytokines by enhancing the B7-2/CD28 costimulatory receptor interaction
- (2016) Revital Levy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials — Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm
- (2015) S. Vessillier et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
- (2015) Isabelle Le Mercier et al. Frontiers in Immunology
- Cytokine release assays: Current practices and future directions
- (2014) D. Finco et al. CYTOKINE
- OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
- (2014) Yannick Bulliard et al. IMMUNOLOGY AND CELL BIOLOGY
- Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies — Impact of effector cells
- (2014) Shan Chung et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
- (2014) Rituparna Das et al. JOURNAL OF IMMUNOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
- (2014) H. S. Kuehn et al. SCIENCE
- Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
- (2014) P. Kvistborg et al. Science Translational Medicine
- Structural Basis for the Recognition of Human Cytomegalovirus Glycoprotein B by a Neutralizing Human Antibody
- (2014) Nadja Spindler et al. PLoS Pathogens
- Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
- (2014) Lidia Robert et al. OncoImmunology
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
- (2013) Aurélien Marabelle et al. JOURNAL OF CLINICAL INVESTIGATION
- Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies
- (2013) Jeong M. Kim et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Polymorphisms and Interspecies Differences of the Activating and Inhibitory Fc RII of Macaca nemestrina Influence the Binding of Human IgG Subclasses
- (2013) H. M. Trist et al. JOURNAL OF IMMUNOLOGY
- Retrocyte Display® technology: Generation and screening of a high diversity cellular antibody library
- (2013) Ekaterina Breous-Nystrom et al. METHODS
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- Basis of CTLA-4 function in regulatory and conventional CD4+ T cells
- (2012) X. Tai et al. BLOOD
- Affinity and Cross-Reactivity Engineering of CTLA4-Ig To Modulate T Cell Costimulation
- (2012) Zhenghai Xu et al. JOURNAL OF IMMUNOLOGY
- Different Adaptations of IgG Effector Function in Human and Nonhuman Primates and Implications for Therapeutic Antibody Treatment
- (2012) M. Warncke et al. JOURNAL OF IMMUNOLOGY
- The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge
- (2012) Randall J. Brezski et al. mAbs
- Tumor Immunotherapy Directed at PD-1
- (2012) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
- (2011) O. S. Qureshi et al. SCIENCE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro
- (2009) M. Leidi et al. JOURNAL OF IMMUNOLOGY
- Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
- (2008) E Oflazoglu et al. BRITISH JOURNAL OF CANCER
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now